Eculizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3123 publications

Practical approach to pregnancy-associated thrombotic microangiopathies: navigating diagnostic challenges in resource-limited settings.

Practical approach to pregnancy-associated thrombotic microangiopathies: navigating diagnostic challenges in resource-limited settings.

Journal: BMJ case reports

Published: April 08, 2026

Family Planning in Neuroinflammatory Disease.

Family Planning in Neuroinflammatory Disease.

Journal: Continuum (Minneapolis, Minn.)

Published: April 02, 2026

Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Journal: Neurologic clinics

Published: April 01, 2026

Evaluating pozelimab in the treatment of CHAPLE disease.

Evaluating pozelimab in the treatment of CHAPLE disease.

Journal: Immunotherapy

Published: March 24, 2026

Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.

Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.

Journal: Hematology (Amsterdam, Netherlands)

Published: March 20, 2026

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: March 16, 2026

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Journal: Health technology assessment (Winchester, England)

Published: March 03, 2026

Haemolytic Uraemic Syndrome Triggered by Non-Shiga Toxin-Producing Enteropathogenic Escherichia coli in a Child: Difficulties in Diagnosis and Treatment.

Haemolytic Uraemic Syndrome Triggered by Non-Shiga Toxin-Producing Enteropathogenic Escherichia coli in a Child: Difficulties in Diagnosis and Treatment.

Journal: Cureus

Published: February 27, 2026

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

The emerging role of complement inhibitory approaches in the treatment of acute sickle cell disease complications.

The emerging role of complement inhibitory approaches in the treatment of acute sickle cell disease complications.

Journal: Expert review of hematology

Published: February 17, 2026

Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy.

Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: February 13, 2026

Recurrent Atypical Hemolytic-Uremic Syndrome (aHUS) Associated With CD46 Genetic Mutation: A Report of a Rare Case.

Recurrent Atypical Hemolytic-Uremic Syndrome (aHUS) Associated With CD46 Genetic Mutation: A Report of a Rare Case.

Journal: Cureus

Published: February 12, 2026

Showing 1-12 of 3,123

Last Updated: 04/28/2026